BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus disease
As a part of ongoing national preparedness efforts against filoviruses, BARDA continues to support Mapp’s monoclonal antibody therapeutic, MBP091, to treat Marburg virus disease (MVD) caused by Marburg virus (MARV). MVD has a fatality rate of 50%, yet currently there are no therapeutics approved by the U.S. Food and Drug Administration (FDA) to treat the disease.